Elucid's FFR-IQ, an AI-powered noninvasive FFR-CT tool, receives FDA clearance for clinical use.
Key Details
- 1FDA cleared Elucid's FFR-IQ software for noninvasive fractional flow reserve estimation from coronary CT angiography (FFR-CT).
- 2The technology uses AI to incorporate coronary anatomy and plaque composition in its assessments.
- 3Elucid becomes the third commercial FFR-CT vendor in the U.S., following Heartflow (2016) and KeyaMed (2022).
- 4The software was developed based on clinician feedback to improve FFR-CT accuracy by considering factors like plaque characteristics.
- 5There is rising interest in FFR-CT technology as coronary CT angiography (CCTA) adoption increases.
Why It Matters
FDA clearance of Elucid's FFR-CT introduces new competition and innovation in noninvasive cardiac assessment. For radiology professionals, this advances AI applications in coronary imaging, emphasizing multimodal integration of anatomical and physiological data.
Source
Cardiovascular Business
Related News
•Radiology Business
FDA Approves SimBioSys AI Tool for Breast Cancer Risk via MRI
SimBioSys received FDA clearance for TumorSight Risk, an AI tool assessing breast cancer recurrence risk using MRI.
•Radiology Business
UC Irvine Implements AI to Find Lung Cancer Screening Candidates
UC Irvine's radiology department developed an NLP tool to identify patients eligible for lung cancer screening from EHR notes.
•Radiology Business
Webinar to Showcase Successful AI Automation in Radiology Workflows
A webinar will provide insights from imaging leaders on expanding and optimizing AI-driven automation in radiology clinical workflows.